ArticlePharmacoEconomics2025
Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach.
Article in PharmacoEconomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Cost-utility and cost-effectiveness analysis of an AI-driven platform for standard postnatal care and breastfeeding: results from the COMLACT study.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Cost-Effectiveness of Tezepelumab Versus Omalizumab in Patients with Severe Uncontrolled Allergic Asthma in Spain.PharmacoEconomics - open · 2026Article
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.Advances in therapy · 2026Article
- The Efficiency of the German Healthcare System: Some Puzzling Findings.The International journal of health planning and management · 2026Article
- Cost-effectiveness analysis of influenza vaccination with high-dose vaccine versus standard-dose quadrivalent vaccine in older adults in Spain.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Application of a Prevalence-Adjusted Cost-Effectiveness Threshold Framework for Pulmonary Arterial Hypertension.PharmacoEconomics · 2026Article
- Comparison of Alternative Outcome Measures in Cost-Effectiveness Analysis: Three Applications Within Oncology.PharmacoEconomics · 2026Article
- Factors influencing the reimbursement decisions of cancer drugs in Spanish National Health System.Health economics review · 2026Article
- Cost-effectiveness of community interventions to promote awareness, testing and treatment of hepatitis B and C in migrant populations in Catalonia.Scientific reports · 2026Article
- Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?PharmacoEconomics - open · 2026Article
- Should the Spanish National Health System Invest in Psychotherapy for Depression? A Microsimulation Cost-Utility Study to Estimate the Economically Justifiable Price of Cognitive Behavioral Therapy Versus Anti-depressant Medication.Applied health economics and health policy · 2026Article
- [Continuous Subcutaneous Apomorphine Infusion Therapy: Economic Impact in Spain].Revista de neurologia · 2026Article
- Cost-Effectiveness Analysis of Etrasimod Compared With Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain.PharmacoEconomics - open · 2026Article
- Cost-Utility Analysis of FreeStyle Libre Systems in People with Type 2 Diabetes Mellitus on Treatment with Basal Insulin and Poor Glycemic Control in Spain.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Cost-Effectiveness Analysis of Abrocitinib Compared with Dupilumab for Adolescents With Severe Atopic Dermatitis in Spain.PharmacoEconomics - open · 2026Article
- Exploring the Generalizability of Foreign Cost-Effectiveness Analysis to Spain Using Data From a Scoping Review of Multinational Studies.PharmacoEconomics · 2026Article
- The Monetary Value of a Statistical Life in the Context of Atherosclerotic Cardiovascular Disease.PharmacoEconomics · 2025Article
- Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study.BMJ public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundKnowing the health opportunity costs of funding decisions is crucial to assess whether the health gains associated with new interventions are larger than the health losses imposed by the displacement of resources. Empirical estimates based on the effect of health spending on health outcomes have been proposed in several countries, including Spain, as a proxy to capture these opportunity costs. However, there is a need to regularly update existing health opportunity cost estimates and to explore the role of omitted variable bias in these estimations.
objectiveThe aim of this paper is to provide an updated and refined estimate of the causal impact of health spending on health in Spain that can be translated into an estimate of the incremental cost per quality-adjusted life-year produced by the Spanish national health system.
methodsWe applied fixed-effect models using data for 17 Spanish regions from 2002 until 2022 to estimate the impact of public health spending on health outcomes and explored the extent of omitted variable bias. Changes in these estimates over time were assessed and alternative specifications were tested.
resultsBased on fixed-effect models with control variables, the estimated spending elasticity was 0.061, which translated into an incremental cost per quality-adjusted life-year of approximately €34,000. The bias-corrected elasticity was 0.075, with a corresponding incremental cost per quality-adjusted life-year of €27,000. We found that the estimated impact of spending on health decreases when recent years of data are added, and that the extent of omitted variable bias appears to increase, particularly when adding the COVID-19 pandemic period.
conclusionsThis study provides an updated estimation of the incremental cost per quality-adjusted life-year produced by the Spanish national health system. The estimates provided can be easily updatable as new data become accessible, and the methods applied might be transferable to other settings with similar available data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.